Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Chemotherapy in Advanced Endometrial Cancer
NCT03503786Phase 2Unknown
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in endometrial cancer (EC), sponsored by National Cancer Institute. Status: unknown.
02
Drugs
avelumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03503786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503786.